Report

reporttype1receiptdateformat102companynumbUS-JNJFOC-20140319327occurcountryUSVersion of Safety Report ID1receivedateformat102duplicate1transmissiondateformat102fulfillexpeditecriteria1Safety Report ID10108953Date Received25/04/2014transmissiondate12/12/2014serious2Date Last Updated25/04/2014primarysourcecountryUS

Receiver

receivertype6receiverorganizationFDA

Primary Source

reportercountryUSqualification5

Sender

sendertype2senderorganizationFDA-Public Use

Patient

Weight135.17SexFemale

Contents

Reaction
- 1)
- 2)
- 3)
- 4)
- 5)
- 6)
- 7)
- 8)
- 9)
- 10)
- 11)
- 12)
- 13)
Drug

Reaction

1)

reactionmeddraversionpt17.0ReactionParkinsonismOutcomeNot recovered/not resolved

2)

reactionmeddraversionpt17.0ReactionAdverse eventOutcomeUnknown

3)

reactionmeddraversionpt17.0ReactionOff label useOutcomeNot recovered/not resolved

4)

reactionmeddraversionpt17.0ReactionBlood pressure fluctuationOutcomeNot recovered/not resolved

5)

reactionmeddraversionpt17.0ReactionBlood glucose abnormalOutcomeNot recovered/not resolved

6)

reactionmeddraversionpt17.0ReactionTrismusOutcomeNot recovered/not resolved

7)

reactionmeddraversionpt17.0ReactionMuscle spasmsOutcomeNot recovered/not resolved

8)

reactionmeddraversionpt17.0ReactionWeight increasedOutcomeNot recovered/not resolved

9)

reactionmeddraversionpt17.0ReactionIncreased appetiteOutcomeNot recovered/not resolved

10)

reactionmeddraversionpt17.0ReactionConstipationOutcomeNot recovered/not resolved

11)

reactionmeddraversionpt17.0ReactionDry mouthOutcomeUnknown

12)

reactionmeddraversionpt17.0ReactionTremorOutcomeUnknown

13)

reactionmeddraversionpt17.0ReactionChest painOutcomeUnknown

Drug

1)

drugcharacterization1medicinalproductINVEGA SUSTENNAdrugauthorizationnumb022264drugdosagetext3 WEEKS AGOdrugdosageformINJECTIONdrugadministrationroute030drugindicationBIPOLAR DISORDERdrugstartdateformat610drugstartdate/03/2014actiondrug4drugrecurreadministration2

openFDA Info on Medication

Application NumberNDA022264Brand NameINVEGA SUSTENNAGeneric NamePALIPERIDONE PALMITATEManufacturersJanssen Pharmaceuticals, Inc.product_ndc50458-560, 50458-561, 50458-562, 50458-563, 50458-564Product TypeHUMAN PRESCRIPTION DRUGRouteINTRAMUSCULARActive IngredientsPALIPERIDONE PALMITATERXCUI858048, 858051, 858052, 858053, 858054, 858055, 858056, 858057, 858073, 858074spl_id86e7f21e-638b-11ea-8ce6-7c2bfc2ca371spl_set_id1af14e42-951d-414d-8564-5d5fce138554Package NDC 50458-560-01, 50458-561-01, 50458-562-01, 50458-563-01, 50458-563-03, 50458-564- ... UNIIR8P8USM8FR

2)

drugcharacterization1medicinalproductINVEGA ERdrugauthorizationnumb021999drugstructuredosagenumb9drugstructuredosageunit003drugdosageformOROS (Oral Osmotic) Therapeutic System Tabletdrugadministrationroute048drugindicationBIPOLAR DISORDERdrugstartdateformat602drugstartdate//2013actiondrug4drugrecurreadministration2

3)

drugcharacterization2medicinalproductZOLOFTdrugdosageformTABLETdrugadministrationroute048drugindicationPRODUCT USED FOR UNKNOWN INDICATIONdrugstartdateformat602drugstartdate//2013drugenddateformat610drugenddate/03/2014

openFDA Info on Medication

Application NumberNDA020990, NDA019839Brand NameZOLOFTGeneric NameSERTRALINE HYDROCHLORIDEManufacturersRoerigproduct_ndc0049-0050, 0049-4960, 0049-4900, 0049-4910Product TypeHUMAN PRESCRIPTION DRUGRouteORALActive IngredientsSERTRALINE HYDROCHLORIDERXCUI208149, 208161, 212233, 312938, 312940, 312941, 861064, 861066spl_id665a145d-44fb-4fef-a3c1-2aac26e0715cspl_set_idfe9e8b7d-61ea-409d-84aa-3ebd79a046b5Package NDC 0049-4960-30, 0049-4960-50, 0049-4900-30, 0049-4900-66, 0049-4900-73, 0049-4900- ... UNIIUTI8907Y6X

4)

drugcharacterization2medicinalproductCOGENTINdrugstructuredosagenumb.5drugstructuredosageunit003drugseparatedosagenumb2drugintervaldosageunitnumb1drugintervaldosagedefinition804drugdosageformUnspecifieddrugadministrationroute065drugindicationADVERSE DRUG REACTION

openFDA Info on Medication

Application NumberNDA012015Brand NameCOGENTINGeneric NameBENZTROPINE MESYLATEManufacturersOak Pharmaceuticals, Inc. (Subsidiary of Akorn, Inc.)product_ndc76478-611Product TypeHUMAN PRESCRIPTION DRUGRouteINTRAMUSCULAR, INTRAVENOUSActive IngredientsBENZTROPINE MESYLATERXCUI885205, 885207spl_id9f21b8d1-371b-472c-9e88-c6a8ee56d051spl_set_idb707bc17-3ab4-47a9-a83e-ebd1d384a9d8Package NDC76478-611-02UNIIWMJ8TL7510

5)

drugcharacterization2medicinalproductBUSPIRONE HCLdrugstructuredosagenumb15drugstructuredosageunit003drugseparatedosagenumb3drugintervaldosageunitnumb1drugintervaldosagedefinition804drugdosageformTABLETdrugadministrationroute048drugindicationPRODUCT USED FOR UNKNOWN INDICATION

openFDA Info on Medication

Application NumberANDA208829Brand NameBUSPIRONE HCLGeneric NameBUSPIRONE HYDROCHLORIDEManufacturersAmneal Pharmaceuticals NY LLCproduct_ndc69238-1115, 69238-1116, 69238-1117, 69238-1118, 69238-1119Product TypeHUMAN PRESCRIPTION DRUGRouteORALActive IngredientsBUSPIRONE HYDROCHLORIDERXCUI866018, 866083, 866090, 866094, 866111spl_id5e00599c-64da-4fe2-a5e1-ebb9d03d959cspl_set_id33999f17-f689-40a1-955a-fb19c0590e0ePackage NDC 69238-1115-1, 69238-1115-5, 69238-1116-1, 69238-1116-5, 69238-1117-1, 69238-1117 ... UNII207LT9J9OC

6)

drugcharacterization2medicinalproductZOLOFTdrugstructuredosagenumb150drugstructuredosageunit003drugseparatedosagenumb1drugintervaldosageunitnumb1drugintervaldosagedefinition804drugdosageformTABLETdrugadministrationroute048drugindicationINSOMNIAdrugstartdateformat610drugstartdate/03/2014

openFDA Info on Medication

Report Duplicate

duplicatesourceJANSSENduplicatenumbUS-JNJFOC-20140319327

Adverse Event Report

Report

Receiver

Primary Source

Sender

Patient

Reaction

1)

2)

3)

4)

5)

6)

7)

8)

9)

10)

11)

12)

13)

Drug

1)

openFDA Info on Medication

2)

3)

openFDA Info on Medication

4)

openFDA Info on Medication

5)

openFDA Info on Medication

6)

openFDA Info on Medication

Report Duplicate

Media

Newsletter

Follow us

Connect with us